Myths vs facts: Pharmakogenetik Medicheck and Blutzucker

The combination of pharmacogenetics and blood sugar is often marketed with exaggerated claims. Fact: Pharmacogenetic tests (e.g., MyBody-X Medicheck) analyze gene variants affecting drug metabolism, such as CYP450 enzymes. This can aid in dosing certain medications. A direct link to blood sugar levels is only indirect, e.g., via genes like SLC30A8 (zinc transporter, T2D risk) or TCF7L2 (insulin resistance). These markers are population-based and not suitable for personalized carbohydrate recommendations. A myth is that a genetic test can precisely tell you how many carbs to eat. The evidence for this is weak (marketing). Blood sugar is influenced by many factors: diet, exercise, stress, sleep, microbiome. A genetic test provides only one small piece. MyBody-X tests cover some relevant genes, but clinical applicability is limited. Beware of overinterpretation: a single SNP does not predict actual blood sugar regulation. For drugs that affect blood sugar (e.g., metformin, statins), pharmacogenetics can offer clues, but not dietary prescriptions. Conclusion: Pharmacogenetics is useful for drug optimization, not for dietary guidance. Blood sugar management requires a holistic approach.